US2005215500A1PendingUtilityA1

Immunostimulatory nucleic acid molecules

64
Assignee: US HEALTHPriority: Jul 15, 1994Filed: Oct 22, 2004Published: Sep 29, 2005
Est. expiryJul 15, 2014(expired)· nominal 20-yr term from priority
Inventors:Arthur M. KriegJoel KlineDennis KlinmanAlfred Steinberg
A61P 37/06A61P 31/12A61P 7/00A61P 37/08A61P 31/00A61P 37/04A61P 31/04A61P 31/10A61P 35/00A61P 33/00A61P 43/00A61P 37/02A61P 17/00A61P 17/06A61P 1/02A61P 19/02A61P 1/04A61P 11/06A61P 1/16A61P 1/00A61K 31/7125A61K 31/711A61K 2039/55561C12N 15/117C12Q 1/68C12N 2310/315A61K 31/00C07H 21/00A61K 31/4706A61K 31/7048A61K 39/39C12N 2310/17A61K 39/00Y02A50/30
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.

Claims

exact text as granted — not AI-modified
1 .- 18 . (canceled)  
     
     
         19 . A composition comprising an immunostimulatory oligonucleotide comprising the formula  
         5′ X 1 X 2 CGX 3 X 4  3′ 
       wherein C is cytosine, G is guanine, C and G are unmethylated, and X 1 , X 2 , X 3 , and X 4  are nucleotides, and 
 wherein the oligonucleotide comprises a diol at either or both termini.  
 
     
     
         20 . The composition of  claim 19 , wherein the diol is at a 5′ terminus.  
     
     
         21 . The composition of  claim 19 , wherein the diol is at a 3′ terminus.  
     
     
         22 . The composition of  claim 19 , wherein the diol is at a 5′ terminus and at a 3′ terminus.  
     
     
         23 . The composition of  claim 19 , wherein the diol is tetraethyleneglycol.  
     
     
         24 . The composition of  claim 19 , wherein the diol is hexaethyleneglycol.  
     
     
         25 . The composition of  claim 19 , wherein X 1 X 2  is GpA.  
     
     
         26 . The composition of  claim 19 , wherein X 3 X 4  is selected from TpC and TpT.  
     
     
         27 . The composition of  claim 19 , wherein the immunostimulatory oligonucleotide comprises a sequence TGACGTT.  
     
     
         28 . The composition of  claim 19 , wherein the immunostimulatory oligonucleotide comprises a sequence TGACGTC.  
     
     
         29 . The composition of  claim 19 , wherein the immunostimulatory oligonucleotide is 8 to 100 nucleotides long.  
     
     
         30 . The composition of  claim 19 , wherein the immunostimulatory oligonucleotide is 8 to 40 nucleotides long.  
     
     
         31 . The composition of any one of claims  19 - 30 , further comprising an antigen.  
     
     
         32 . The composition of  claim 31 , wherein the composition is a vaccine.

Join the waitlist — get patent alerts

Track US2005215500A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.